Infliximab

Back to the list
Eurofins Biomnis code

INFAC

Synonyms
  • anti-Infliximab antibodies
  • Flixabi
  • Inflectra
  • Infliximab
  • Remicade
  • Remsima
  • Zessly
Specialty

Immunology

Clinical significance

Infliximab is a human/mouse chimeric monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFalpha. TNFalpha is produced by the body's cells and promotes inflammation, particularly in chronic inflammatory diseases such as chronic inflammatory bowel diseases (Crohn's disease, ulcerative colitis) or inflammatory rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis). Anti-infliximab antibodies may develop in response to treatment. They may have no clinical consequences or, conversely, may be responsible for a loss of clinical remission. Infliximab and anti-infliximab antibody levels should be measured in cases of loss of clinical response to biotherapies, drug optimisation, change of drug class, addition of an immunosuppressant, dose reduction or discontinuation of treatment.

Preanalytics
  • A tube specifically for this analysis : No
Further information

Please attach the specific clinical information sheet (R46 : Anti-TNF)

Documents to download
Methodology

Chemiluminescence

Turnaround time

8 days

Testing Laboratory

Biomnis Lyon

Contact(s)
Customer Care